New Licensing Program Facilitates Adoption of Tandem Mass Tag Technology
Thermo Fisher Scientific helps research service providers and their customers optimize protein identification and quantitation
"CST is pleased to license TMT technology from Thermo Fisher Scientific, which will add power to our proteomics services by delivering unparalleled quantitative protein analysis. We expect this technology will enable us to help our pharma and academic customers accelerate their pre-clinical discovery research"

Dateline:

Carslbad, CA
 

Thursday, May 4, 2017 12:30 pm EDT

Research service providers and their customers are now set to benefit from a new licensing program specifically designed to facilitate and optimize the use of the Thermo Scientific™ Tandem Mass Tag™ protein identification and quantitation technology.

The Thermo Fisher Scientific licensing program enables service providers to leverage the power of Thermo Scientific™ TMT™ technology to cater to the analytical needs of their customers for more reproducible quantitative proteomics. Cell Signaling Technology (CST), a specialized provider of research products and services and an early licensee, is already realizing the benefits of the quantitative multiplex technology.

“There is an increased market demand for the unique analytical capabilities of the TMT technology, as well as for service providers with the necessary skills and equipment to perform that type of analysis. We are very excited about growing the use of this technology and having the ability to offer it through CST’s service business,” said Navid Haghdoost, director, Protein Biology Product Management, Thermo Fisher Scientific.

The TMT technology uses tandem mass spectrometry (MS/MS) to provide consistent and accurate simultaneous identification and quantitation of proteins in up to 10 different samples derived from cells, tissues or biological fluids. The technology features an enhanced multiplex capability resulting in fewer missing quantitative values as the level of TMT multiplexing increases.

“CST is pleased to license TMT technology from Thermo Fisher Scientific, which will add power to our proteomics services by delivering unparalleled quantitative protein analysis. We expect this technology will enable us to help our pharma and academic customers accelerate their pre-clinical discovery research,” said Roberto Polakiewicz, chief scientific officer at CST.

For more information about TMT technology, please visit: www.thermofisher.com/TMT     

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

About CST

Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing the world’s highest quality, innovative, research and diagnostic products to accelerate biological understanding and enable personalized medicine. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.

CST Media and Press

Rebecca J. Reppucci, MBA

Cell Signaling Technology, Inc.

Director of Marketing Communications

Phone: 978-867-2382

 Email: marketingpr@cellsignal.com